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Background: Cysteine proteases of the papain superfamily are present in nearly
all groups of eukaryotes and play vital roles in a wide range of biological
processes and diseases, including antigen and hormone processing, bacterial
infection, arthritis, osteoporosis, Alzheimer’s disease and cancer-cell invasion.
Because they are critical to the life-cycle progression of many pathogenic
protozoa, they represent potential targets for selective inhibitors. Chagas’ disease,
the leading cause of death due to heart disease in Latin American countries, is
transmitted by Trypanosoma cruzi. Cruzain is the major cysteine protease of
T. cruzi and has been the target of extensive structure-based drug design.
Results: High-resolution crystal structures of cruzain bound to a series of
potent phenyl-containing vinyl-sulfone, sulfonate and sulfonamide inhibitors have
been determined. The structures show a consistent mode of interaction for this
family of inhibitors based on a covalent Michael addition formed at the enzyme’s
active-site cysteine, hydrophobic interactions in the S2 substrate-binding
pocket and a strong constellation of hydrogen bonding in the S1′ region. 
Conclusions: The series of vinyl-sulfone-based inhibitors examined in complex
with cruzain was designed to probe recognition and binding potential of an
aromatic-rich region of the enzyme. Analysis of the interactions formed shows that
aromatic interactions play a less significant role, whereas the strength and
importance of hydrogen bonding in the conformation adopted by the inhibitor upon
binding to the enzyme was highlighted. A derivative of one inhibitor examined is
currently under development as a therapeutic agent against Chagas’ disease.
Introduction
Chagas’ disease, or American trypanosomiasis, is the
leading cause of heart disease in Latin American countries
[1]. The disease, transmitted by the protozoan parasite
Trypanosoma cruzi, affects more than 25 million people
annually in South America and causes more than 45,000
deaths per year. Another ninety million people are
believed to be at risk of infection [2]. T. cruzi takes on
several distinct physical forms during its life cycle.
Humans are infected with the trypomastigote form of the
parasite via the bite of a blood-sucking insect. Once the
trypomastigote enters the human bloodstream it can
invade cardiac muscle tissue where it transforms to an
intracellular amastigote. Amastigotes replicate within the
cell, transform back into trypomastigotes and then rupture
the cell. This rupture releases an amplified stock of the
infectious form of the parasite back into the host’s blood-
stream. Specific enzymes have been shown to be crucial
for the progression of the parasite’s life cycle. Cruzain
(also known as cruzipain, gene product gp75151), the
major cysteine protease of T. cruzi, is one such enzyme
[3–5], making it a prime candidate as a therapeutic target
for treatment of Chagas’ disease.
As a class of enzymes, cysteine proteases are important in
the degradative processing of peptides and proteins [6].
They exhibit widespread participation in physiological and
pathological pathways like antigen processing, prohormone
activation, bond remodeling, arthritis, Alzheimer’s disease,
cancer-cell invasion, apoptosis, as well as the life-cycle
processes of pathogenic protozoa [6–8]. The ubiquitous
nature and presence of cysteine proteases has made them
the subject of intensive study. The discovery or design of
selectively specific inhibitors of cysteine proteases repre-
sents great therapeutic potential. Towards that end, numer-
ous strategies have been explored [6,9,10]. Compounds that
form reversible interactions with the thiol of the active-site
cysteine residue by mimicking the covalent adduct that is
initially made during catalytic degradation include peptidyl
aldehydes [11], diamino ketones [12] and nitriles [13]. The
formation of irreversible covalent linkages via alkylation of
the active-site cysteine has been accomplished using
epoxysuccinyl [14], peptidyl Michael acceptors [15–17],
halomethyl ketones and (acyloxy)methyl ketones [18]. 
The active-site region of cruzain is similar to those of other
members of the papain superfamily of cysteine proteases.
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Its seven substrate-binding subsites, four (S4, S3, S2, S1)
[16] on the acyl side and three (S1′, S2′, S3′) on the amino
side of the cleaved substrate bond, line a cleft between the
two structural domains of the molecule (Figure 1). This
cleft contains cruzain’s catalytic triad, Cys25, His159, and
Asn175, as well as the highly conserved Trp177. Whereas
considerable effort has been expended in optimizing the
interactions of inhibitors at the S1 and S2 binding sites
[16,17], far less is known about the interactions possible at
S1′. The high-resolution crystal structure of cruzain shows
that there is a large open surface bounded by Trp177 in the
prime site region [19]. Design of compounds to exploit this
cavity would provide potential for enhanced inhibitor
interactions. This concept has been explored in the case of
another cysteine protease, cathepsin K, which has an
active-site region similar to that of cruzain. X-ray crystal
structures of cathepsin K in complex with symmetric pep-
tidyl ketone inhibitors have shown these compounds to
span both the prime and non-prime surfaces of the active-
site groove. Two pi–pi aromatic interactions exist between
two Cbz phenyl groups and Trp184 and Tyr67 (cathepsin
K numbering) on the prime and non-prime sides, respec-
tively [12,20]. A high-resolution X-ray crystallographic
structure of cathepsin K covalently bound to a dipeptidyl-
vinyl-sulfone inhibitor, APC3328, shows that the phenyl
moiety of the phenyl-sulfonyl unit, although occupying the
space defined by the S1′ pocket, does not make optimal
contacts with the available prime site residues [21]. 
Early work in protease inhibitor synthesis showed that
peptidyl-based Michael acceptors were effective inactiva-
tors of papain, with second-order rate constants from 0.05
to 70 M–1s–1 [22]. To serve as effective pharmaceutical
candidates these inhibitors had to be engineered to display
selectivity between different members of the papain
superfamily in vivo as well as in vitro. Towards this end the
catalytic mechanism of the individual enzymes as well as
their known substrate selectivity was considered [23].
Vinyl-sulfone moieties, which act as Michael acceptors,
provide a polarized yet inert unsaturated bond as well as
available hydrogen-bond acceptors in the form of the sul-
fonyl unit. Therefore, vinyl sulfones suggested a promis-
ing general scaffold that could be exploited in a variety of
versatile and stereospecific synthetic schemes [9]. A high
degree of success has been achieved in the design of vinyl-
sulfone-containing inhibitors, as illustrated by compounds
that have been shown to be unreactive against serine pro-
teases, metalloproteases, aspartyl proteases, nonactive site
cysteines and circulating thiols such as glutathione.
The historical base of knowledge of vinyl-sulfone
inhibitors combined with the recent structural studies of
cathepsin K provided the impetus for design of inhibitors
against cruzain. A series of vinyl-sulfonate and sulfon-
amide inhibitors was synthesized to probe for additional
potency and selectivity that could be gained from interac-
tions with the prime-side residues of cysteine proteases
[24]. Second-order rate constants for inhibition for the
series examined here clearly indicate that potency against
cruzain is directly correlated to both the length of the
linker between the sulfonyl unit and the prime-site-
directed aromatic group as well as to the electronic nature
of the linking atom(s). High-resolution crystal structures
of cruzain bound to a series of four vinyl-sulfonyl-contain-
ing compounds have been solved to detail the interactions
achieved between inhibitor and protease. Elucidation of
the prime-site binding yielded a scenario that was differ-
ent from the predicted outcome of a strong hydrogen-
bonding network about the vinyl-sulfonyl unit combined
with aromatic interactions with Trp177.
Results
Kinetics of inhibition
The chemical structures of the series of vinyl-sulfone
phenyl inhibitors explored in this study are shown in
Figure 2. They maintain the common groups of phenylala-
nine (Phe) and homophenylalanine (hPhe) at the P2 and
P1 sites, respectively. The group occupying the loosely
defined P3 region varies between a Cbz group with a
planar aromatic group in VSII and VSIII, and non-planar
aliphatic groups present in the morpholino urea (Mu) and
N-methyl-piperazinyl urea (N-Mpip) units in VSI and
VSIV, respectively. The overall length of the inhibitors
increases throughout the series, with the molecular masses
of the compounds ranging from 560 to 660. The point of
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Figure 1
Active-site cleft of cruzain. The catalytic triad (residues Cys25, His159
and Asn175) is highlighted. Gln19 and Trp177, which are important
for inhibitor binding are also shown. This figure was prepared with the
programs MolScript [41] and Raster3D [42].
addition of atoms is between the vinyl-sulfone moiety and
the aromatic group designed to occupy the aromatic-rich
region bounded by Trp177 of cruzain. As shown in
Table 1, the inhibitory potency of these compounds,
reflected by second-order rate constants, increases from
0.32 × 106 to 6.5 × 106 M–1s–1 with increasing length of the
spacer connecting the sulfonyl unit and the P1′ phenyl
residue. Inhibitors VSI–VSIII were synthesized according
to the methods described in Roush et al., [24]. Details of
the synthesis of VSIV will be reported elsewhere (WRR,
unpublished results).
Crystallization and structure determination
All complexes of cruzain with the vinyl-sulfonyl inhibitors
(from here on referred to simply by the name of the
inhibitor) crystallized in the space group P21. Unit-cell
parameters are shown in Table 2. VSI crystallized with
three molecules in the asymmetric unit whereas the
remaining complexes each had one molecule per asymmet-
ric unit. The packing of VSI was similar to that of VSII and
VSIII. The length of the b axis of this complex is approxi-
mately three times that of the b axis of VSII and VSIII,
representing the stacking of the asymmetric unit’s three
distinct molecules. The three molecules are related to one
another by noncrystallographic symmetry, with a slight
rotation relative to one another about the crystal’s b axis.
The crystal structures of VSI–VSIV were solved via mol-
ecular replacement with subsequent refinement to 2.2, 1.6,
1.8 and 2.0 Å, respectively. Data collection, phasing and
refinement statistics for all four complex structures are
shown in Table 2. Details pertaining to data collection,
structure solution and refinement can be found in the
Materials and methods section. Initial Fo–Fc electron-
density maps contoured at 3σ calculated from the molecu-
lar replacement showed clear density for the inhibitor
molecule of each complex structure. Figure 3 shows initial
Fo–Fc electron density contoured at 2.5σ for VSIII. This
map is representative of those calculated for each complex.
In each structure, all atoms that were ultimately refined to
the resolution limit of the data were visible to at least 1.5σ
above background in the first difference electron density
map calculated. Simulated-annealing omit maps calculated
at 2.5σ at the end of the refinement process confirmed the
presence, positioning and detailed orientation of each of
the vinyl-sulfonyl inhibitor molecules. 
Complex structure
Common features
Each vinyl-sulfonyl inhibitor forms a covalent irreversible
attachment to cruzain. A Michael addition, involving
nucleophilic attack by Sγ of the active-site cysteine
residue, Cys25, occurs at the vinyl carbon adjacent to the
hPhe moiety. This creates a covalent bond between
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Figure 2
Chemical formulae of inhibitors VSI, VSII, VSIII and VSIV. The subsite
position of individual moieties is indicated, according to the notation of
Schechter and Berger [15].
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Table 1
Kinetics of vinyl-sulfone inhibitors against cruzain.
Compound IC50 (nM) kinact/Ki or kass (M–1×sec–1)
VSI 8 0.319 × 106
VSII 3 1.965 × 106 ± 0.116
VSIII 1 4.33 × 106 ± 0.30
VSIV <1 6.5 × 106 ± 0.30
enzyme and inhibitor. Structures VSI–VSIV all contain a
P2 phenylalanine moiety, which binds in the S2 pocket of
cruzain. A hydrogen bond is formed between the peptide
nitrogen of the phenylalanine moiety of each inhibitor and
cruzain’s backbone at the carbonyl of Gly66. Cruzain’s S2
pocket is the enzyme’s most well defined substrate-
binding cleft and is lined with hydrophobic residues
Leu67, Ala133 and Leu157 that readily accommodate the
phenylalanine of each inhibitor. These two areas of inter-
action define the anchoring of the inhibitors on the non-
prime side of cruzain’s binding groove. The hPhe moiety
extends into the solvent in structures VSI–VSIII and does
not form constructive interactions with any part of cruzain.
In VSIV, which packs in a different crystal form, the hPhe
shows some distant weak contacts (of the order of 3–4 Å)
with Phe39 of a symmetry-related molecule. The phenyl
ring of the hPhe moiety is the least well ordered common
feature of each inhibitor, with B factors that range from 9%
higher than the average B of the inhibitor molecule for the
best ordered hPhe to 65% higher for the least well ordered. 
One vinyl-sulfone oxygen of each inhibitor consistently
makes several hydrogen bonds with cruzain. Contacts
between Gln19 Nε2 and the vinyl-sulfone oxygen are 2.9,
3.1, 2.8 and 2.9 Å in structures VSI–VSIV, respectively.
Contacts between Gln19 Oε1 and the oxygen are 3.6, 3.5,
3.4 and 3.5 Å, respectively. His159 Nδ1 interacts with the
vinyl-sulfone oxygen at distances of 3.1, 3.2, 3.7 and 3.4 Å.
The constellation of contacts is completed by those with
Trp177 Nε1 at distances of 3.3, 3.2, 3.5 and 3.2 Å with
VSI–VSIV, respectively. 
Superposition of the complex structures using all non-
hydrogen atoms of cruzain as the superposition set shows
834 Structure 2000, Vol 8 No 8
Table 2
Crystallographic parameters, data collection and refinement statistics.
VSI VSII VSIII VSIV
Crystallographic parameters
Unit-cell dimensions
a (Å) 45.23 44.99 45.18 36.02
b (Å) 155.46 51.28 51.36 51.59
c (Å) 45.86 45.40 45.56 54.16
β (°) 116.22 116.09 116.17 99.74
Space group P21 P21 P21 P21
Molecules per asymmetric unit 3 1 1 1
Data collection statistics
Resolution limit (Å) 2.15 1.6 1.7 2.0
Number of unique reflections (F >0σ|F|) 25,466 23,603 15,513 12,860
Rmerge (%)* 10.5 5.9 8.0 11.8
Redundancy of reflections
overall 7.8 5.6 7.8 4.6
highest resolution shell 1.1 1.5 1.7 3.6
<I/σ(I)>
overall 8.3 16.5 12.4 9.7
highest resolution shell 3.3 2.7 2.5 4.3
Completeness
overall (%) 82.6 95.7 88.8 96.3
highest resolution shell (%) 68.1 82.8 74.4 95.0
Resolution range; highest shell (Å) 2.21–2.15 1.65–1.60 1.85–1.80 2.06–2.00
Refinement statistics
Resolution range (Å) 30.0–2.15 30.0–1.6 30.0–1.8 30.0–2.0
Rcryst (%)† 18.5 18.4 17.3 17.6
Rfree (%)‡ 20.8 21.9 20.3 22.6
Rmsd
bond lengths (Å) 0.006 0.006 0.007 0.006
bond angles (°) 1.4 1.4 1.5 1.4
Water molecules 61 82 66 87
Average B factor (Å2)
complex 11.55 17.14 15.53 10.60
inhibitor 20.38 19.33 18.95 15.29
*Rmerge = (Σh Σi(Ihi – 〈Ih〉))/Σh I, where Ih is the mean structure-factor
intensity of i observations of symmetry-related reflections with Bragg
intensity index h. †Rcryst = (Σh Σi(Fobs–Fcalc)/Σ Fobs), where
Fobs and Fcalc are the observed and the calculated structure-factor
magnitudes. ‡Rfree = Σ(hkl)τ  Fobs(hkl)  – kF(hkl)/Σ(hkl)τ Fobs(hkl),
where the τ set of reflections is omitted from the refinement process;
10% of the data were included in the τ set.
notable consistency in the positioning of the inhibitor
molecules (Figure 4). Chemical features that are con-
served amongst the inhibitors occupy the same space in
each structure, including the Phe, hPhe and vinyl-sulfone
moieties. The identical Cbz group of VSII and VSIII
superimpose nearly exactly, as do the similar Mu and
N-pip groups of VSI and VSIV. The varied substituents
attached to the vinyl-sulfone group probe the region
bounded by the shallow surface of the P1′ binding area
and will be detailed individually. 
VSI
Because there are no atoms separating the vinyl-sulfone
sulfur atom and the phenyl ring, the position of the phenyl
ring is determined entirely by the electrostatic contacts
made by the vinyl-sulfone oxygen (Figures 5a,6a). The
phenyl ring sits such that it is nearly perpendicular to (and
3.5 Å away from) the six-membered ring of Trp177. In this
orientation the ring shows an end-on aromatic interaction
with the indole ring of Trp177. In addition, the inhibitor’s
phenyl ring points towards the sidechain of Met142.
Met142 is quite flexible and is observed in four different
conformations in the four complexes examined. In VSI this
residue is in an extended conformation. Its closest contact
to any of the vinyl-sulfone phenyl ring atoms is 3.5 Å. The
planar faces of the phenyl ring of the vinyl sulfone and that
of the hPhe moieties are nearly parallel to one another.
With more than 6 Å separating these ring faces, no pi-stack-
ing interactions are formed. The vinyl-sulfone oxygen not
involved in hydrogen bonds to the protein binds to an
ordered water molecule at a distance of 2.8 Å
VSII
In this inhibitor a methylene group separates the vinyl
sulfone and the phenyl ring, providing greater length as
well as additional degrees of freedom for the orientation of
the phenyl ring. Neither of these factors positions the ring
in the aromatic-rich P1′ region bounded by Trp177.
Instead the vinyl-sulfone phenyl ring is bent back towards
the phenyl ring of the hPhe moiety, forming an end-on aro-
matic interaction with approximately 4 Å separation. The
effect is a near cyclization of the inhibitor molecule that
seems to decrease the water-accessible surface of these two
hydrophobic arms of the inhibitor (Figures 5b,6b).
VSIII
The inhibitor of this structure contains an ester linkage
between the vinyl-sulfonyl group and para-nitrophenol.
Electron density for five of the six ring atoms is visible in a
simulated-annealing omit map contoured at 2.5σ. Density
for the nitro group is not well resolved. Whereas the nitro-
gen atom is well-resolved, the density visible for the two
oxygens is less distinct. This suggests that the nitro group
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Figure 3
Stereoview of VSIII bound to cruzain. Electron
density (contoured at 2.5σ) from an initial
Fo–Fc map is shown. Although not used in the
calculation of the map, the inhibitor has been
included for clarity. This figure was prepared
with the program BobScript [43].
Structure
Figure 4
Superposition (see text) of VSI, VSII, VSIII and VSIV in the active-site
cleft of cruzain. The coordinates of VSII are used for the ribbon
respresentation. This figure was prepared with the programs MolScript
[41] and Raster3D [42].
is spinning about the axis defined by the bond between
the phenyl ring and the group’s nitrogen. The nitro group,
therefore, occupies a variety of conformations simultane-
ously in the crystal, a fact reflected by elevated B factors
(1.5 times higher than the inhibitor’s average B factor).
The nitro group makes no electrostatic contacts. Met142 is
again found in a mostly extended conformation and the
nitro phenyl ring of the inhibitor points towards this
residue’s sidechain (Figures 5c,6c). The nitro phenyl ring
does not extend towards the aromatic-rich region of
cruzain but instead aligns nearly parallel to (and ~8 Å away
from) the hPhe phenyl ring.
VSIV
This inhibitor is the longest of the four, with a hydroxy-
lamine unit linking the vinyl-sulfone group to the attached
phenyl ring. The conformation of VSIV is similar to the rest
of the series, with the P1′ O-benzyl hydroxylamino unit
curving away from the protein. There are no aromatic–aro-
matic interactions between the P1′ vinyl-sulfone phenyl
ring and Trp177 of cruzain. Instead, the inhibitor com-
pletes its network of hydrogen bonding about a sulfonyl
oxygen and seems to nest its extended form in the shelf
defined by Ser139, Met142 and Asp158 (Figures 5d,6d).
This end of the inhibitor–enzyme structure is further stabi-
lized by contacts with two ordered water molecules. The
hydroxylamine oxygen bonds to a water molecule at a dis-
tance of 3.3 Å. The vinyl-sulfone oxygen not involved in
electrostatic interactions with the protein contacts the same
water molecule at a distance of 3.2 Å. This vinyl-sulfone
oxygen also has distant contact with a water molecule 3.6 Å
away, a water molecule that also makes contact with the
protein backbone at the carbonyl oxygen of Gly22.
Discussion
On the basis of the structure of human cathepsin K bound
to a peptidyl-phenyl vinyl-sulfone inhibitor [21], a con-
structive hydrogen-bonding network between VSI–VSIV
and the sidechains lining cruzain’s active-site canyon was
expected. The human cathepsin K structure reported by
McGrath et al. [21] demonstrated that hydrogen bonds
were formed between a sulfonyl oxygen and both Gln19
and Trp177. The phenyl ring adjacent to the sulfone
occupied what is described as the P1′ binding site for
cathepsin K, an area bounded by Asn158, Trp177 and
Ala136. This inhibitor showed no additional stabilizing
aromatic–aromatic interactions between the sulfone
phenyl ring and the ring system of Trp177. When the
crystal structure of cathepsin K was solved in the presence
of a variety of potent (non-vinyl sulfone containing)
inhibitors that spanned both the non-prime and prime
sites of the active-site cleft, constructive pi–pi stacking
interactions were observed between phenyl moieties and
Trp177 [12,20]. The quality of the aromatic–aromatic
interactions was, in part, dependent upon the length of
the inhibitor. These available cathepsin K complexes,
which illustrate very different inhibitor scaffolds, sug-
gested that a series of vinyl-sulfonyl-based inhibitors that
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Figure 5
The cruzain active site with bound inhibitor.
Cruzain is shown in ribbon representation,
and inhibitors are shown in ball-and-stick
representation (in cyan). Amino acid
sidechains involved in binding are highlighted
in magenta. Bound water molecules are
displayed in red. Hydrogen bonds are
indicated by dashed lines. (a) VSI, (b) VSII,
(c) VSIII, (d) VSIV. This figure was prepared
with the programs MolScript [41] and
Raster3D [42].
varied in length and contained a terminal aromatic moiety
could possess the beneficial qualities of hydrogen-bond
formation at the sulfonyl oxygens as well as constructive
aromatic interactions with Trp177 in the P1′ binding site.
Structure–function relationship of Trp177
Trp177 is widely conserved throughout the papain super-
family of lysosomal cysteine proteases [25]. It is believed
that this residue plays a critical role in substrate cleavage
by orienting the enzyme’s catalytic machinery. The indole
ring of Trp177 helps position the protease’s catalytic triad
asparagine in an orientation conducive to interaction with
the triad’s histidine via a pi-NH interaction. This inter-
action facilitates the formation of the thiolate–imidazolium
ion pair necessary for catalysis (RJF, unpublished data).
Because it plays this necessary functional role, it is not sur-
prising to find this tryptophan residue widely conserved
throughout cysteine proteases. Tryptophan plays other
important roles in protein structure and function, many of
which capitalize upon the sidechain’s large available
surface area and the environment it draws. (For a review of
this topic see [26] and references therein.) Tryptophan
sidechains are commonly associated with key centers of
binding energy in protein–protein and protein–ligand
interactions. On the basis of the change in free energy
(∆∆G) associated with mutation to alanine of a tryptophan
sidechain involved in a heteromolecular interaction, tryp-
tophan was commonly found (along with tyrosine and argi-
nine) to contribute ≥ 2 kcal/mol–1 of binding energy [27].
One proposed explanation for this strong contribution by
tryptophan highlights the different modes of interaction
possible for this residue, including aromatic pi interactions,
hydrogen-bond donor interactions as well as hydrophobic
surface area presentation. When analysis of the surround-
ings of tryptophan residues in protein structures was per-
formed, distinct patterns relevant to the interactions of
VSI–VSIV in cruzain’s S1′ binding site were observed.
The tryptophan sidechain forms interactions with other
sidechains that occur, in order of their frequency of occur-
rence, as face-on, edge-on, or via hydrogen bonds at Nε1
[26]. These observations further support the hypothesis
that the positioning of the vinyl-sulfone phenyl-containing
inhibitors in the vicinity of Trp177 would offer binding
specificity and stabilization to complex formation.
Determinants of P1′ interactions
Structures VSI–VSIV showed results that differed from the
prediction made on the basis of the structures of cathepsin K.
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Figure 6
Surface representation of the cruzain active-
site region. Hydrophobic residues are
indicated in green. (Note that the sides of the
S2 pocket are lined with hydrophobic
patches.) The surfaces of amino acids of
interest (see text) are labeled and color coded:
Gln19 and His159, cyan; Asp158 and
Ser139, magenta; Cys25 and Met142, yellow.
Inhibitor molecules are displayed as sticks.
(a) VSI, (b) VSII, (c) VSIII, (d) VSIV. This figure
was prepared with the program GRASP [44].
In each cruzain complex structure three hydrogen bonds
are formed between a vinyl-sulfonyl oxygen and hydro-
gen-donor sidechains of cruzain. The electrostatic contri-
butions of these interactions are strong enough to
outweigh any other potential interactions. They lock the
inhibitor in the observed orientation in the complex and
effectively prevent any other positioning of the prime-side
end of the molecule. In order to preserve the hydrogen-
bonding network, very highly strained conformations
would have to be adopted by the inhibitors in order to
direct the phenyl moiety towards Trp177. Length of the
inhibitor probably contributes to the observed results,
although it is not the sole determining factor. Whereas the
molecule would need to be twisted into an energetically
unfavorable conformation, inhibitor VSIV can theoretically
be positioned such that its phenyl ring stacks against
Trp177. Perhaps additional linking atoms between the
vinyl sulfone and a pi-electron-rich terminal moiety would
offer enough degrees of freedom to make such a bonding
scenario possible. As Figure 6 illustrates, the substituents
in the current series of the vinyl-sulfone inhibitors pre-
dominantly sit on top of the shelf formed by residues
Ser139, Met142 and Asp158 instead of adopting an orien-
tation that would allow for aromatic–aromatic interactions
with Trp177. Figures 5 and 6 also illustrate the P1′ binding
pocket available to this series of inhibitors, namely the
region bounded by Gln19, Ala136, Asp158, His159 and
Trp177. The complex of a fifth cruzain structure with an
inhibitor analagous to VSIII but lacking the nitro group
also shows a strong hydrogen-bonding constellation from a
vinyl-sulfonyl oxygen. This is further evidence of the elec-
trostatic interaction potential of these Michael acceptor
compounds. As no electron density is visible for any atoms
of the phenyl ester that were predicted to extend into the
amino-side binding pockets of the enzyme [24], further
comment cannot be made regarding this molecule’s prime
site (S Gillmor, unpublished results).
The hydrogen-bonding network created by the presence
of the vinyl-sulfonyl group is not only sufficient to posi-
tion this end of each inhibitor studied, it influences the
orientation of one of the sidechains that form cruzain’s
active-site constellation. In VSI–VSIV, the positions of
His159 are nearly perfectly superimposable. In a 1.9 Å
structure of cruzain covalently bound to an inhibitor that
terminates at the bond formed with the Sγ of Cys25 (LSB,
unpublished results), Nδ1 of the imidazole ring of His159
is not tethered with a hydrogen bond. Electron density for
the ring is clearly visible and shows that the ring is rotated
28° out of the plane defined by the comparable imidazole
rings in the cruzain VSI–VSIV structures.
Participation of hPhe
The shape that the inhibitor adopted in the VSII
complex structure, with the phenyl moiety of the sulfone
unit directed towards the P1 hPhe residue, was the most
different from that predicted for the series. In order to
investigate whether the observed conformation was a
function of disorder in the crystal packing, crystals of the
VSII complex grown by the same procedure as those
used for the initial structure solution were treated with
cryoprotecting conditions and flash-cooled with liquid
nitrogen, and a low-temperature data set was collected.
The resulting structure showed the same positioning and
conformation of the inhibitor. In both the room-tempera-
ture and low-temperature structures, no electron density
suggestive of any alternative conformations exists for the
vinyl-sulfone phenyl ring. 
The P1 moiety in structures VSI–VSIV is hPhe. It was also
the P1 residue in the vinyl-sulfone phenyl-inhibitor-bound
structure of human cathepsin K. In the human cathepsin K
structure, hPhe lay in the S1 pocket, which is a loosely
defined groove on one wall of the binding cleft. Mainchain
and carbonyl atoms from one domain of cathepsin K make
van der Waals contacts with the hPhe, offering some stabil-
ity to this group [21]. In VSI–VSIII, the hPhe residue is
completely solvent exposed and forms no interactions with
cruzain. A different crystal-packing arrangement in VSIV
allowed for weak hydrophobic contacts with a symmetry-
related molecule but no enhancing interactions with the
cruzain molecule to which the inhibitor was bound. It has
been shown that the inclusion of a non-naturally occurring
amino acid in dipeptide or peptidomimetics based on
dipeptidyl cysteine protease inhibitors is crucial for pre-
serving the half-life and stability of the inhibitor. Their
inclusion also greatly reduces toxicity of the inhibitor, as
was demonstrated in an animal model of Chagas’ disease
[28]. Because a naturally occurring dipeptide yields meta-
bolic products that limit in vivo half-life and might inhibit
the Krebs cycle of the host organism [29], they have been
avoided in inhibitors designed for use as therapeutic
agents. Historically, homophenylalanine has also been con-
sidered a favorable moiety for inclusion in substrate-based
designed inhibitors because it lacks beta and gamma
branching that could result in steric conflicts with the
enzyme [25]. On the basis of the structures reported here,
the presence of hPhe does not seem to enhance interac-
tions between inhibitor and enzyme. Future generations of
designed inhibitors against cruzain will seek to incorporate
a non-naturally occurring group that is sterically appropri-
ate as well as beneficial to either solubility or binding effi-
ciency of the molecule.
Biological implications
Chagas’ disease affects more than 25 million people
annually in Southern and Central America. The disease
is caused by infection with the protozoan parasite Try-
panosoma cruzi and is responsible for 45,000 deaths per
year [2]. Blocking the activity of cruzain, the major cys-
teine protease from T. cruzi, prevents the parasite from
completing its life cycle. Structure-based drug design of
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inhibitors of cruzain represents an effective route to
finding and optimizing therapeutic agents for the treat-
ment of Chagas’ disease.
Cruzain is a 212 amino acid papain-superfamily cysteine
protease that has an extended substrate-binding site
located between the protease’s two domains. The active
site can accommodate seven amino acids, four on the acyl
side (S1–S4) and three on the amino side (S1′–S3′) of the
cleaved bond. Early design of inhibitors against cruzain
focused on the acyl side pockets of the enzyme. Vinyl-sul-
fonyl-derived inhibitors, which contain functional groups
that extend into the amino side binding pockets, are effec-
tive in in vitro assays against cruzain [24,30]. One
member of this family of inhibitors also has suitably high
stability, bioavailablity and low toxicity for animal-model
studies. This compound has demonstrated potency in res-
cuing mice from the acute phase of a lethal experimental
T. cruzi infection as well as clearing parasitemia in
chronically infected mice [28]. On the basis of these data,
safety studies of this compound are currently being con-
ducted in dogs [31]. High-resolution crystal structures of
vinyl-sulfonyl inhibitors in complex with cruzain have
elucidated the structural correlates of binding. This infor-
mation will be used to direct further synthetic modifica-
tion to enhance the potential of such compounds as
chemotherapeutic agents to combat the growing burden
of both human and domestic animal parasitic infection. 
Materials and methods
Determination of kinetic parameters: IC50 determinations
Inhibitors were screened for effectiveness against cruzain using purified
recombinant protein lacking the C-terminal domain. (This construct was
designed to minimize naturally occurring C-terminal heterogeneity. It
expresses, refolds and activates in a manner comparable with that of
protein expressed from the wild-type gene) [32]. Enzyme (4 nM) was
incubated with 1–10,000 nM inhibitor in 100 mM NaAcetate pH 5.5, 10
mM dithiothreitol (DTT) (buffer A) for 5 min at room temperature. Z-Phe-
Arg-AMC (ZFRAMC, Bachem) was added to 20 µM in a final volume of
200 µl, and the increase in fluorescence (excitation at 355 nm and emis-
sion at 460 nm) was followed with an automated microtiter plate spec-
trofluorometer (Labsytems Fluoroskan II). Inhibitor stocks were prepared
at 20 mM in dimethylsulfoxide (DMSO), and serial dilutions were made
in DMSO [33]. Controls of enzyme alone, enzyme with DMSO and
enzyme with a previously known effective irreversible inhibitor, K11002
(morpholino urea-Phe-HPhe-vinylsulfonebenzene, Axys Pharmaceuticals
Inc., South San Francisco, CA) [34], were run with each assay set.
Inhibitors that had an inhibitory concentration (IC50) of less than 1 µM
were analyzed further.
Kinetic assays of irreversible inhibitors
Kinetic analyses of the vinyl-sulfone phenyl derivative cysteine protease
inhibitors were performed as follows [4,33]. Cruzain (2 nM) in 100 µl of
assay buffer was added to inhibitor dilutions in 100 µl of 5 µM Z-Phe-
Arg-AMC (Km = 1 µM) in buffer A. Progress curves were obtained for 
5 min at room temperature (less 5% of substrate consumed) with dilu-
tions of inhibitor, starting at 10 µM down to 20 nM (10 × the concentra-
tion of enzyme). Inhibitor dilutions that gave simple exponential progress
curves over a wide range of kobs were used to determine kinetic parame-
ters. The value of kobs, the rate constant for loss of enzyme activity, was
determined from an equation for pseudo first order dynamics using
UltraFit (Biosoft). When kobs varied linearly with inhibitor concentration
kass was determined by linear regression analysis. (It was not possible to
demonstrate saturation kinetics for some of the enzyme–inhibitor combi-
nations discussed in this paper, owing to the range of inhibitor concen-
trations that were studied. Accordingly, inhibition constants in Table 1
are reported as kass; see [33]). If the variation was hyperbolic, indicating
saturation inhibition kinetics, kinact and Ki were determined from an equa-
tion describing a two step irreversible inhibitor mechanism:
(kobs = kinact[I]o/([I]o + Ki*(1 + [S]o/Km)))
and non linear regression analysis using UltraFit. 
Preparation, purification and crystallization of cruzain bound
to inhibitors
Cruzain was expressed and purified as described previously
[17,32,35]. Activated cruzain was incubated overnight with molar
excess amounts of inhibitor dissolved in either DMSO or dimethylfor-
mamide (DMF). This prevented further proteolytic activity and achieved
complexation of the enzyme and inhibitor. After passage over a MonoQ
column on an ÄKTA Explorer system (Amersham Pharmacia Biotech
Inc.), fractions containing pure cruzain bound to inhibitor were concen-
trated via vacuum dialysis against 2 mM bis tris pH 5.8 to a final con-
centration of 10–12 mg ml–1 for crystallization. Crystals were obtained
by the hanging-drop method against a grid of 0.6–1.0 M sodium
citrate, pH 5.5–7.0. Drops of cruzain bound to vinyl-sulfone, sulfonate,
or sulfonamide inhibitor that were equilibrated at 18°C for 24 h were
microseeded with existing crystals of cruzain bound to another cova-
lently bound inhibitor (LSB, unpublished results). After 7–12 days,
small crystals of cruzain bound to vinyl-sulfone inhibitor appeared.
These crystals were crushed and diluted 104- or 105-fold to produce
seeding solutions. New hanging drops of cruzain bound to vinyl-sulfone
inhibitor that had been equilibrated at 18°C for 24 h were microseeded
with 1 µl of diluted seeding stock solution. Data collection quality crys-
tals (150–300 µm per edge) grew to maximum size within three weeks. 
Data collection, structure solution and crystallographic
refinement
All data were collected at room temperature on conventional rotating-
anode X-ray sources. Data from three crystals were merged to produce
the 2.15 Å data set for VSI. Data sets for VSII–VSIV were all collected
from a single crystal each. An R-axis IIc detector fitted with Yale MSC
mirrors and a Rigaku RU-H3R rotating-anode operating at 100 mA,
50 kV was used for this complex. For VSII (1.6 Å), VSIII (1.7 Å) and
VSIV (2.0 Å), a Mar Research image plate scanner fitted with Supper
mirrors and a Rigaku RU-200 rotating-anode operating at 90 mA and
50 kV was used for data collection. All data were integrated and scaled
using the HKL package of software [36]. Table 2 summarizes data pro-
cessing statistics. 
The structures VSI and VSII were solved by molecular replacement
using AMoRe [37]. The 1.9 Å structure of cruzain bound to another
covalently bound peptidyl inhibitor was used as a search model, exclud-
ing the inhibitor molecule and all water molecules (LSB, unpublished
results). The structures of VSIII and VSIV were solved using X-PLOR
[38], using the 1.6 Å structure of VSII, excluding the inhibitor molecule
and all water molecules, as a search model. The unit-cell parameters of
VSII and VSIII were similar enough that explicit molecular replacement
searching was probably not necessary, but for the sake of consistency
this structure was solved according to the same procedure as the
others in the vinyl-sulfone series. One unique solution was easily found
for each complex with the exception of VSI, which contained three
unique molecules per asymmetric unit. The R factors resulting from mol-
ecular replacement prior to refinement for cruzain VSI–VSIV were
36.4%, 31.4%, 28.7%, 35.6%, respectively. Starting models and para-
meter sets for each inhibitor molecule were generated with Moloc [39].
Initial placement of the inhibitor models in each structure were made via
inspection of Fo–Fc difference electron-density maps calculated from
the molecular replacement solution and contoured at 3σ. Subsequent
model adjustment and refinement (positional and individual B factor)
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were accomplished with CHAIN and X-PLOR [38,40]. Explicit noncrys-
tallographic symmetry was imposed throughout the refinement of VSI,
as the position of the three molecules were related to one another by a
small rotation about the crystal’s b axis. Simulated-annealing omit maps
calculated with a 5 Å radius around the omitted inhibitor molecule were
used to confirm placement and orientation of each inhibitor molecule.
Water molecules were added manually with the requirement that they
be located in strong difference electron-density peaks (≥ 3σ) and within
acceptable hydrogen-bonding distance and geometry.
Accession numbers
The coordinates for VSI, VSII, VSIII and VSIV have been deposited in
the Protein Data Bank with accession numbers 1F29, 1F2A, 1F2B and
1F2C, respectively.
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